Drug Profile
NV 1030
Latest Information Update: 18 Apr 2002
Price :
$50
*
At a glance
- Originator MediGene Inc
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Apr 2002 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 13 Jun 2001 No-Development-Reported for Cancer in Canada (Unknown route)
- 26 Jan 2001 NeuroVir Therapeutics has been acquired by MediGene AG and is now called MediGene Inc